glp-1 for high blood pressure A Comprehensive Review of the Role of Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Glucose, Cholesterol, and Blood American drugmakers pushed GLP1 therapies

Conclusion GLP-1 RAs may significantly lower the combined risk of mortality and hospitalization in patients with HFpEF

If no evidence of retinopathy is found and glycemic control is stable, examinations every 1-2 years may be considered

Ozempic Lawsuit Timeline & News July 2026 June 1, 2026: More Than 125 Lawsuits Join GLP-1 MDL as Eli Lilly Asks for Dismissal of Plaintiffs Experts With the GLP-1 MDL reaching 3,763 total cases as of June 1, Eli Lilly, the manufacturer of Ozempic, has requested that the judge dismiss the plaintiffs experts

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG

Proprietary Flatter Me Enzyme Blend 125mg Diastase* * Manufacturer does not disclose amount

Key Timeline Dates: August 2, 2023: First lawsuit filed by Jaclyn Bjorklund February 2024: MDL 3094 created, cases consolidated July 3, 2024: Mass Eye & Ear NAION study published December 2024: 1,300 pending cases January 2026: 3,063 pending cases (more than doubled) May 14, 2025: Critical hearing scheduled on admissibility of expert causation testimony Settlement Projections (Not Actual Payouts) Attorney Estimates No Settlements Finalized Important Disclaimer: No global settlements have been announced as of January 2026